You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海利生物(603718.SH):公司及兩個子公司累計收到政府補助合計約288.14萬元
格隆匯 07-12 16:37

格隆匯7月12日丨海利生物(603718.SH)公吿,根據上海市發展和改革委員會《關於新型冠狀病毒診斷與治療創新品種研發及產業化特備專項第二批項目的批覆》,公司全資子公司上海捷門生物技術有限公司申報的“新型冠狀病毒特異性IgM/IgG檢測試劑(及關鍵原材料)的研發及產業化”項目於2021年7月9日獲得99萬元的扶持資金。

據悉,公司於2020年12月8日披露了《海利生物關於獲得政府補助的公吿》,自該公吿披露至2021年7月9日,公司、全資子公司上海捷門生物技術有限公司以及控股子公司楊凌金海生物技術有限公司累計收到政府補助合計人民幣約288.14萬元,其中與資產相關的政府補助合計人民幣130萬元,佔公司2020年度經審計的歸屬於上市公司股東的淨資產的0.12%與收益相關的政府補助合計人民幣約158.14萬元,佔公司2020年度經審計的歸屬於上市公司股東的淨利潤的17.72%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account